S4.5b A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan—pharmacokinetic results

S4.5 MYCETOMA CLINICAL TRIAL ON FOSRAVUCONAZOLE TREATMENT IN EUMYCETOMA– TOP LINE RESULTS, SEPTEMBER 22, 2022, 10:30 AM - 12:00 PM:   OBJECTIVE: To evaluate the pharmacokinetics (PK) of fosravuconazole (measured as ravuconazole) and itraconazole in patients with mild to moderate eumycetoma caused by...

Descripción completa

Detalles Bibliográficos
Autores principales: Brüggemann, Roger, Nyaoke, Borna, Ahmed, Eiman Siddig, Siddig, Emanwell Edwar, Egondi, Thaddaeus, Oyieko, Peelen, Bakhiet, Sahar Mubarak, Zijlstra, Eduard E, Fahal, Ahmed H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Oral Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516221/
http://dx.doi.org/10.1093/mmy/myac072.S4.5b

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516221/
http://dx.doi.org/10.1093/mmy/myac072.S4.5b

Ejemplares similares